Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael J. Corbley

A Novel Small-Molecule Inhibitor of Transforming Growth Factor Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth in Vivo and Prevents Tumor Recurrence After Surgical Resection

Cancer Research

Oncology

2007

English

SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Arteriosclerosis, Thrombosis, and Vascular Biology

Cardiovascular Medicine

Cardiology

2008

English

Related publications

Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-Β Type I Receptor Kinase Inhibitor

Cancer Research

Oncology

2006

English

Dihydropyrrolopyrazole Transforming Growth Factor-B Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series With Selectivity Versus Transforming Growth Factor-B Type II Receptor Kinase and Mixed Lineage Kinase-7

English

Hematein, a Casein Kinase II Inhibitor, Inhibits Lung Cancer Tumor Growth in a Murine Xenograft Model

International Journal of Oncology

Cancer Research

Oncology

2013

English

Small-Molecule P21-Activated Kinase Inhibitor PF-3758309 Is a Potent Inhibitor of Oncogenic Signaling and Tumor Growth

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2010

English

GH3 Pituitary Tumor Cells Contain Heteromeric Type I and Type II Receptor Complexes for Transforming Growth Factor and Activin-A

Journal of Biological Chemistry

English

Regulation of Murine Type 1 Plasminogen Activator Inhibitor Gene Expression in Vivo. Tissue Specificity and Induction by Lipopolysaccharide, Tumor Necrosis Factor-Alpha, and Transforming Growth Factor-Beta.

Journal of Clinical Investigation

Medicine

1991

English

Type I Transforming Growth Factor Β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase

Journal of Biological Chemistry

English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports

Multidisciplinary

2019

English

Soluble Tumor Necrosis Factor Receptor Type I Enhances Tumor Development and Persistence in Vivo

Cellular Immunology

Immunology

2000

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael J. Corbley

A Novel Small-Molecule Inhibitor of Transforming Growth Factor Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth in Vivo and Prevents Tumor Recurrence After Surgical Resection

SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Related publications

Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-Β Type I Receptor Kinase Inhibitor

Dihydropyrrolopyrazole Transforming Growth Factor-B Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series With Selectivity Versus Transforming Growth Factor-B Type II Receptor Kinase and Mixed Lineage Kinase-7

Hematein, a Casein Kinase II Inhibitor, Inhibits Lung Cancer Tumor Growth in a Murine Xenograft Model

Small-Molecule P21-Activated Kinase Inhibitor PF-3758309 Is a Potent Inhibitor of Oncogenic Signaling and Tumor Growth

GH3 Pituitary Tumor Cells Contain Heteromeric Type I and Type II Receptor Complexes for Transforming Growth Factor and Activin-A

Regulation of Murine Type 1 Plasminogen Activator Inhibitor Gene Expression in Vivo. Tissue Specificity and Induction by Lipopolysaccharide, Tumor Necrosis Factor-Alpha, and Transforming Growth Factor-Beta.

Type I Transforming Growth Factor Β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Soluble Tumor Necrosis Factor Receptor Type I Enhances Tumor Development and Persistence in Vivo